Unite Us and Ride Health Partner to Improve Access to Transportation Services for New Yorkers
The Collaborative Initiative with Social Care Networks Will Overcome Obstacles to Vital Services Following New York State’s Approval of the 1115 Medicaid Waiver
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
“Sean Lyden MD, Professor and Chairman Vascular Surgery Cleveland Clinic on the mainstage at ISET 2024”
SIRPant Immunotherapeutics Strengthens Board of Directors with Appointment of Roger Sawhney, M.D.
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
– Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025
– Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs
– Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties
SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors